Create a narrative

Akeso Community

SEHK:9926 Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 20 Analysts

Cadonilimab And Ivonescimab Trials Will Broaden Market Access

Key Takeaways Akeso's strategic focus on bispecific antibodies and NRDL inclusion could drive significant revenue growth and expand market access. Collaborations and a robust R&D pipeline signal long-term growth and potential market expansion, bolstering future earnings and global positioning.

HK$103.57

FV

19.1% undervalued

55.40%

Revenue growth p.a.

0

0

1

12 days ago